Saturday 17 October 2026 Export TVTX’s income statement to Excel — free account

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 48.2%, EPS fell 164.3%, free cash flow grew 604.2% and total debt rose 93.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

49.62 3.17 −6.00%

Follow TVTX

Alert me

Market cap: $5.0B
P/E: 0.0×
Fwd P/E: 196×
Dividend yield: —
F-score: 6/9
Altman Z: 1.78
Beneish M: −1.74
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 99.70

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	6	3	12	1	12	10	2	—	1	9	—

Insider Ownership 2.18%

Capital & Financial Ratios $m

Market Cap 4,980.00

Revenue 591.33

Net Income (43.46)

Free Cash Flow 15.16

Net Debt 113.60

Current Ratio 4.05

Debt/Equity 24.58

P/E ratio 0.00

Fwd P/E 196.00

P/S ratio 7.84

P/B ratio 189.16

Past 5Y EPS Growth —

This Y EPS Growth 89.44%

Next Y EPS Growth 10,421.23%

Next Y revenue growth 47.66%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 78.07%

10-year low 10-year high

P/B against its own 10 years 97.13%

10-year low 10-year high

EV/Sales against its own 10 years 80.43%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	567	371	323	489
Receivables	21	27	80	81
Inventory	9	6	6	8
Other	—	—	—	—
	617	417	438	615

	2023	2024	2025	Q'26
Payables	42	24	25	7
ST’ Debt	—	—	—	—
Other	5	17	3	2
	178	201	160	152

Compound Annual Growth %

	10y	5y	3y
Sales	17.25%	19.87%	64.89%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(9.16%)	(11.48%)	38.90%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	127	170	—	—	—
’25	82	114	165	130	491
’24	41	54	63	75	233
’23	31	32	37	45	145
’22	48	54	28	(21)	109
’21	47	55	68	(38)	132
’20	48	48	51	51	198

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(40)	58	—	—	—
’25	(42)	5	14	61	38
’24	(119)	(40)	(43)	(36)	(237)
’23	(81)	(69)	(59)	(70)	(280)
’22	(55)	(37)	(40)	(55)	(186)
’21	(26)	6	32	(27)	(15)
’20	(29)	(6)	7	(14)	(43)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(63)	37	—	—	—
’25	(54)	(7)	(1)	41	(20)
’24	(125)	(52)	(51)	(45)	(274)
’23	(109)	(73)	(64)	(76)	(322)
’22	(61)	(48)	(47)	(59)	(215)
’21	(36)	2	27	(32)	(39)
’20	(34)	(11)	0	(22)	(67)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.40)	(0.37)	—	—	—
’25	(0.47)	(0.14)	0.28	0.03	(0.29)
’24	(1.76)	(0.91)	(0.70)	(0.73)	(4.08)
’23	(1.27)	(1.13)	1.97	(1.18)	(1.50)
’22	(1.20)	(1.05)	(1.09)	(1.03)	(4.37)
’21	(0.96)	(0.64)	(0.59)	(0.84)	(3.01)
’20	0.02	(0.58)	(0.44)	(2.37)	(3.56)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	11.60	15.55	20.09	10.87	8.98	12.75	17.97	5.25	5.12	12.91	Analyst estimates 2026–2028 Powerpack
	High	24.57	26.44	33.00	24.69	28.19	33.09	31.51	23.18	20.33	42.13
People
People	Employees	135	173	214	221	262	310	462	380	385	497
	Revenue/emp, $m	0.99	0.90	0.77	0.79	0.76	0.43	0.24	0.38	0.61	0.99
Income, $m
Income, $m	Revenue	134	155	164	175	198	132	109	145	233	491
	Gross margin, %	96.59	97.67	96.63	97.01	96.91	97.10	95.96	92.12	96.68	97.89
	EBT	(58)	(58)	(102)	(146)	(189)	(217)	(331)	(376)	(321)	(49)
	EBT margin, %	(43.10)	(37.67)	(62.02)	(83.52)	(95.19)	(164.51)	(302.54)	(258.96)	(137.45)	(10.04)
	Net income	(48)	(60)	(103)	(146)	(169)	(180)	(278)	(111)	(322)	(26)
	Depreciation	18	20	22	55	35	26	22	33	41	58
Per share, $
Per share, $	Revenue	3.61	4.00	4.06	4.14	4.17	2.20	1.72	1.96	2.96	5.50
	Earnings	(1.29)	(1.54)	(2.54)	(3.46)	(3.56)	(3.01)	(4.37)	(1.50)	(4.08)	(0.29)
	Cash flow	(0.09)	0.19	(0.62)	(1.37)	(0.90)	(0.25)	(2.92)	(3.77)	(3.01)	0.42
	Capex	(0.32)	(0.36)	(0.49)	(0.37)	(0.52)	(0.40)	(0.45)	(0.57)	(0.46)	(0.65)
	Free cash flow	(0.42)	(0.17)	(1.10)	(1.74)	(1.42)	(0.65)	(3.37)	(4.34)	(3.47)	(0.23)
	Book value	8.32	7.56	7.87	5.22	4.44	5.05	0.67	2.70	0.75	1.29
	Shares, m	37	39	40	42	48	60	64	74	79	89
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	5.11	5.62	5.57	3.43	6.53	14.09	12.03	4.89	5.89	6.95
	P/B	2.22	2.97	2.88	2.72	6.14	6.15	30.74	3.54	23.26	29.69
	EV/Sales	3.53	3.97	3.89	2.32	5.80	11.61	11.35	3.58	5.63	6.92
	EV/FCF	(30.66)	(93.19)	(14.30)	(5.52)	(17.08)	(39.31)	(5.78)	(1.61)	(4.80)	(161.30)
Cash, $m
Cash, $m	Operating cash flow	(3)	7	(25)	(58)	(43)	(15)	(186)	(280)	(237)	38
	Capex	(12)	(14)	(20)	(16)	(25)	(24)	(29)	(42)	(36)	(58)
	Free cash flow	(15)	(7)	(45)	(74)	(67)	(39)	(215)	(322)	(274)	(20)
Balance, $m
Balance, $m	Working capital	249	240	391	334	318	459	344	439	216	278
	Total debt	44	45	195	205	215	227	376	377	310	312
	Net debt	(211)	(256)	(276)	(194)	(146)	(326)	(75)	(190)	(60)	(11)
	Shareholders’ equity	308	293	318	221	211	302	43	201	59	115
Returns, %
Returns, %	ROA	(9.23)	(11.42)	(16.70)	(22.29)	(27.95)	(26.02)	(38.43)	(15.24)	(46.50)	(4.26)
	ROIC	(37.78)	(89.46)	(119.67)	(311.81)	(169.48)	0.00	0.00	(2,161.70)	0.00	(37.84)
	ROE	(15.76)	(19.88)	(33.59)	(54.29)	(78.37)	(70.17)	(161.46)	(91.44)	(247.45)	(29.38)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%	Compare
DFTX Definium Therapeutics, Inc.	$4.6B	— (loss-making)	—	—	n/m	−78.31% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.0B	—	—	+101.55%	—	−23.34%	0.00%	0.00%

All 614 Biotechnology stocks →